- Avalo Therapeutics press release (NASDAQ:AVTX): FY EPS of -$114.00 may not be comparable to consensus of -$16.80.
- Revenue of $1.92M (-89.4% Y/Y) beats by $0.72M.
- As of December 31, 2023, Avalo had $7.4 million in cash and cash equivalents.
More on Avalo Therapeutics
feed from seekingalpha.com